Biofrontera Future Growth
Future criteria checks 2/6
Biofrontera is forecast to grow earnings and revenue by 57.3% and 25.4% per annum respectively while EPS is expected to grow by 64.6% per annum.
Key information
57.3%
Earnings growth rate
64.6%
EPS growth rate
| Pharmaceuticals earnings growth | 17.9% |
| Revenue growth rate | 25.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 31 Aug 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 61 | -10 | N/A | N/A | 1 |
| 12/31/2024 | 47 | -11 | N/A | 1 | 2 |
| 12/31/2023 | 36 | -25 | N/A | -16 | 2 |
| 6/30/2023 | 29 | -23 | -28 | -28 | N/A |
| 3/31/2023 | 28 | -14 | -18 | -18 | N/A |
| 12/31/2022 | 29 | -1 | -16 | -16 | N/A |
| 9/30/2022 | 28 | -12 | -29 | -29 | N/A |
| 6/30/2022 | 28 | -26 | -24 | -24 | N/A |
| 3/31/2022 | 29 | -29 | -25 | -25 | N/A |
| 12/31/2021 | 24 | -38 | -27 | -27 | N/A |
| 9/30/2021 | 24 | -23 | -6 | -6 | N/A |
| 6/30/2021 | 22 | -10 | -6 | -6 | N/A |
| 3/31/2021 | 19 | -10 | -9 | -9 | N/A |
| 12/31/2020 | 19 | -11 | -12 | -12 | N/A |
| 12/31/2019 | 26 | -11 | -38 | -38 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AI10 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AI10 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AI10 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AI10's revenue (25.4% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: AI10's revenue (25.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AI10's Return on Equity is forecast to be high in 3 years time